Chinese Medical Sciences Journal ›› 2022, Vol. 37 ›› Issue (3): 275-281.doi: 10.24920/003936
去甲乌药碱：一种潜在的冠心病诊断心肌负荷药物
张娜娜1,李子健2,*(
),朱海波3,*()
- 1中国农业科学院农产品加工研究所,北京100091,中国
2北京大学第三医院心内科、血管医学研究所,卫生部心血管分子生物学与调节肽重点实验室,分子心血管学教育部重点实验室,心血管受体研究北京市重点实验室,北京100191,中国
3中国医学科学院北京协和医学药物研究所,天然药物活性物质与功能国家重点实验室新药作用机制研究与药效学评价北京重点实验室,北京100007,中国
-
收稿日期:2021-05-16接受日期:2022-01-23出版日期:2022-09-30发布日期:2022-06-26 -
通讯作者:李子健,朱海波 E-mail:lizijian@bjmu.edu.cn;zhuhaibo@imm.ac.cn
Higenamine as a Potential Pharmacologic Stress Agent in the Detection of Coronary Artery Disease
Nana Zhang1,Zijian Li2,*(),Haibo Zhu3,*()
- 1Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences, Beijing 100050, China
2Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences Ministry of Education, and Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100050, China
3State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
-
Received:2021-05-16Accepted:2022-01-23Published:2022-09-30Online:2022-06-26 -
Contact:Zijian Li,Haibo Zhu E-mail:lizijian@bjmu.edu.cn;zhuhaibo@imm.ac.cn
摘要：
心肌灌注显像在冠心病的诊断、预后和管理中具有重要价值。当前,血管扩张剂和肾上腺素剂是最常见的心肌负荷药物。然而,这些药物在部分病人中的应用有限制,并且有多种副反应。因而,有必要开发可以在更多病人中应用的心肌负荷药物。去甲乌药碱是一种β受体激动剂,被批准作为心肌负荷药物应用于心肌缺血的诊断。因其正性肌力作用,去甲乌药碱有望成为用于冠心病诊断的心肌灌注显像负荷药物。本综述总结了去甲乌药碱在心肌灌注显像中的应用,包括其作用机制、给药方式、有效性及安全性。
引用本文
Nana Zhang, Zijian Li, Haibo Zhu. Higenamine as a Potential Pharmacologic Stress Agent in the Detection of Coronary Artery Disease[J].Chinese Medical Sciences Journal, 2022, 37(3): 275-281.
"
"
| Year | Author | Tracer | Analysis | Sample size | Age (y/d) Mean | Male (%) | Sensitivity (%) | Specificity (%) | Accuracy (%) | Positive predictive value (%) | Negative predictive value (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 | Zhou W[ | Tc-99m | SPECT | 62 | 61 | 65 | 65.5 | 84.9 | 75.8 | 79.2 | 73.7 |
| 2012 | Tian R[ | Tc-99m | SPECT | 128 | 58 | 58 | 56.0 | 78 | 67 | 75 | 62 |
| 2012 | Cao Y[ | Tc-99m | SPECT | 62 | 65 | 63 | 57.9 | 91.7 | 71.0 | 91.7 | 57.9 |
| 2014 | Du YR[ | Tc-99m | SPECT | 109 | 58 | 54 | 56.1 | 78.8 | 67.0 | 74.4 | 62.1 |
| 2015 | Mi HZ[ | Tc-99m | SPECT | 60 | 56 | 60 | 69.0 | 80.6 | 75.0 | 76.9 | 73.5 |
| 2015 | Sun Y[ | Tc-99m | SPECT | 100 | 57 | 56 | 76.5 | 93.8 | 93.8 | 76.5 | 32.0 |
| 2018 | Bai H[ | / | Echocar- diography | 90 | 49 | 57 | 28.9 | 89.7 | 57.1 | 76.5 | 47.8 |
| 1. |
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. Circulation 2022; 145(8): e153-e639. doi: 10.1161/CIR.0000000000001052.
doi: 10.1161/CIR |
| 2. |
Li DL, Kronenberg MW. Myocardial perfusion and viability imaging in coronary artery disease: clinical value in diagnosis, prognosis, and therapeutic guidance. Am J Med 2021; 134(8): 968-75. doi: 10.1016/j.amjmed.2021.03.011.
doi: 10.1016/j.amjmed.2021.03.011 |
| 3. |
Eldirani M, Chehab O, Hassan H, et al. Variations in the referral patterns to pharmacologic and exercise myocardial perfusion imaging. J Nucl Cardiol 2018; 25(5): 1708-14. doi: 10.1007/s12350-017-1071-0.
doi: 10.1007/s12350-017-1071-0 pmid: 28948527 |
| 4. |
Nguyen TH, Horowitz JD, Unger SA, et al. pharmacologic stress myocardial perfusion imaging: differential implications in multi-vessel ischemia. Am J Cardiovasc Dis 2012; 2(1): 34-42. doi: 10.3917/rmm.021.0123.
doi: 10.3917/rmm.021.0123 |
| 5. |
Argulian E, Po JR, Uretsky S, et al. Comparison of the current reasons for undergoing pharmacologic stress during echocardiographic and radionuclide stress testing. J Nucl Cardiol 2017; 24(2): 546-54. doi: 10.1007/s12350-016-0398-2.
doi: 10.1007/s12350-016-0398-2 pmid: 26911366 |
| 6. |
Haberkorn SM, Haberkorn SI, Bönner F, et al. Vasodilator myocardial perfusion cardiac magnetic resonance imaging is superior to dobutamine stress echocardiography in the detection of relevant coronary artery stenosis: a systematic review and meta-analysis on their diagnostic accuracy. Front Cardiovasc Med 2021; 8: 630846. doi: 10.3389/fcvm.2021.630846.
doi: 10.3389/fcvm.2021.630846 |
| 7. |
Van Tosh A and Nichols KJ. Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned? J Nucl Cardiol 2018; 25(3): 828-32. doi: 10.1007/s12350-016-0771-1.
doi: 10.1007/s12350-016-0771-1 pmid: 28074408 |
| 8. |
Tamarappoo BK, Lee FL, Cerqueira M, et al. Independent prognostic value of left ventricular contractile reserve and chronotropic response in patients with reduced left ventricular ejection fraction undergoing vasodilator stress myocardial perfusion imaging with Rb-82 positron emission tomography. Eur Heart J Cardiovasc Imaging 2018; 19(4): 442-9. doi: 10.1093/ehjci/jex157.
doi: 10.1093/ehjci/jex157 pmid: 28673042 |
| 9. |
Geleijnse ML, Elhendy A, Fioretti PM, et al. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000; 36(7): 2017-27. doi: 10.1016/s0735-1097(00)01012-3.
doi: 10.1016/s0735-1097(00)01012-3 pmid: 11127435 |
| 10. |
Pagnanelli RA, Camposano HL. Pharmacologic stress testing with myocardial perfusion Imaging. J Nucl Med Technol 2017; 45(4): 249-52. doi: 10.2967/jnmt.117.199208.
doi: 10.2967/jnmt.117.199208 pmid: 29042473 |
| 11. |
Johnson SG, Peters S. Advances in pharmacologic stress agents: focus on regadenoson. J Nucl Med Technol 2010; 38(3): 163-71. doi: 10.2967/jnmt.109.065581.
doi: 10.2967/jnmt.109.065581 pmid: 20724531 |
| 12. |
Kosuge T, Yokota M. Letter: Studies on cardiac principle of aconite root. Chem Pharm Bull (Tokyo) 1976; 24(1): 176-8. doi: 10.1248/cpb.24.176.
doi: 10.1248/cpb.24.176 |
| 13. |
Zhang N, Lian Z, Peng X, et al. Applications of Higenamine in pharmacology and medicine. J Ethnopharmacol 2017; 196: 242-52. doi: 10.1016/j.jep.2016.12.033.
doi: S0378-8741(16)31083-2 pmid: 28007527 |
| 14. | Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Meidcal College. Over six decades of inheritance, development, and innovation at the Institute of Materia Medica of the Chinese Academy of Medical Sciences - Past, present, and future for a big blueprint for a Healthy China. Chinese. Available from: https://www.imm.ac.cn//lbtp/417a4063fd154c7b890ce312417f809e.htm. Accessed: May 5, 2022. |
| 15. |
Wen J, Li M, Zhang W, et al. Role of higenamine in heart diseases: a mini-review. Front Pharmacol 2021; 12: 798495. doi: 10.3389/fphar.2021.798495.
doi: 10.3389/fphar.2021.798495 |
| 16. |
Kosuge T, Yokota M, Nagasawa M. [Studies on cardiac principle in Aconite roots. I. Isolation and structural determination of higenamine]. Yakugaku Zasshi 1978; 98(10): 1370-5. doi: 10.1248/yakushi1947.98.10_1370.
doi: 10.1248/yakushi1947.98.10_1370 pmid: 34017 |
| 17. |
Chen Y, Guo B, Zhang H, et al. Higenamine, a dual agonist for beta 1- and beta 2-adrenergic receptors identified by screening a traditional Chinese medicine library. Planta Med 2019; 85(9-10): 738-44. doi: 10.1055/a-0942-4502.
doi: 10.1055/a-0942-4502 |
| 18. |
Yu F, Kong L, Wang S. Influence of racemic higenamine on the sinus node. Exp Ther Med 2013; 5(2): 591-5. doi: 10.3892/etm.2012.813.
doi: 10.3892/etm.2012.813 pmid: 23403401 |
| 19. |
Zhang N, Zhu H, Li Z, et al. A novel beta2-AR agonist, Higenamine, induces beta-arrestin-biased signaling. Sci China Life Sci 2021; 65(7): 1357-68. doi: 10.1007/s11427-021-2008-1.
doi: 10.1007/s11427-021-2008-1 pmid: 34783996 |
| 20. |
Wang W, Bian J, Li Z. Internalized activation of membrane receptors: from phenomenon to theory. Trends Cell Biol 2021; 31(6): 428-31. doi: 10.1016/j.tcb.2021.03.008.
doi: 10.1016/j.tcb.2021.03.008 pmid: 33858767 |
| 21. |
Zhang N, Qu K, Wang M, et al. Identification of higenamine as a novel alpha 1 -adrenergic receptor antagonist. Phytother Res 2019; 33(3): 708-17. doi: 10.1002/ptr.6261.
doi: 10.1002/ptr.6261 pmid: 30648306 |
| 22. | Chen ZZ, Liu L, Zhou TJ, et al. Effect of Asarum heterotropoides on the left ventricular function of dogs. Yao Xue Xue Bao 1981; 16(10): 721-7. Chinese. |
| 23. | Liu XJ, Tao Z, Shi RF, et al. Experimental study of a new pharmacological stress test agent-igenamine. Chinese Circ J 1997; 12(4): 304-7. |
| 24. | Zhang Z, Liu XJ, Tao ZH, et al. Effects of higeramine on hemodynamics and its tolerability and safety, an experimental study. Natl Med J China 2002; 82(5): 352-5. |
| 25. | Zheng YL, Shen R, Yang MF, et al. Experimental study of pharmaceutic stress myocardial perfusion imaging with higenamine. Chin J Cardiol 2005; 33(5): 473-5. Chinese. |
| 26. |
Huang NH, Zhou YP, Liu WH, et al. Comparison of cardiovascular effects of aconite root and higenamine in dogs. Acta Pharmacol Sin 1980; 1(1): 34-9. Chinese.
pmid: 6121445 |
| 27. |
Lo CF, Chen CM. Acute toxicity of higenamine in mice. Planta Med 1997; 63(1): 95-6. doi: 10.1055/s-2006-957619.
doi: 10.1055/s-2006-957619 pmid: 9063102 |
| 28. |
Mann A, Williams J. Considerations for stress testing performed in conjunction with myocardial perfusion imaging. J Nucl Med Technol 2020; 48(2): 114-21. doi: 10.2967/jnmt.120.245308.
doi: 10.2967/jnmt.120.245308 pmid: 32277063 |
| 29. |
Feng S, Jiang J, Hu P, et al. A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects. Acta Pharmacol Sin 2012; 33(11): 1353-8. doi: 10.1038/aps.2012.114.
doi: 10.1038/aps.2012.114 pmid: 23085737 |
| 30. |
Du YR, Li F, Xu RY, et al. Tolerability of higenamine hydrochloride in healthy volunteers. Chin J Clin Pharm 2007; 23(4): 258-60. Chinese. doi: 10.13699/j.cnki.1001-6821.2007.04.012.
doi: 10.13699/j.cnki.1001-6821.2007.04.012 |
| 31. |
Zhou W, Wang F, Zhang LL, et al. Myocardial perfusion imaging with higenamine hydrochloride stress studies in diagnosis of coronary artery disease. Chin J Necl Med Mol Imaging 2012; 32(6): 408-12. Chinese. doi: 10.3760/cma.j.issn.2095-2848.2012.06.002.
doi: 10.3760/cma.j.issn.2095-2848.2012.06.002 |
| 32. | Tian R, Wang Q, Mi HZ, et al. Efficacy and safety of higena-mine hydrochlrodide injection used in pharmacological stress myocardial perfusion imaging. Chin J Clin Pharm 2012; 28(2): 88-90. |
| 33. |
Cao Y, Wang ZZ, Wang F, et al. Dectection of coronary heart disease with 99Tcm-MIBI myocardial perfusion imaging stressed by intravenous infusion of higenamine hydrochloride. Chin J Nucl Med Mol Imaging 2012; 32(3): 203-5. Chinese. doi: 10.3760/cma.j.issn.2095-2848.2012.03.010.
doi: 10.3760/cma.j.issn.2095-2848.2012.03.010 |
| 34. |
Du YR, Wang Q, Li DF, et al. Efficacy and safety of a novel pharmacological stress test agent-higenamine in radionuclide myocardial perfusion imaging: phase II clinical trial. Chin J Nucl Med Mol Imaging 2014; 34(1): 34-8. Chinese. doi: 10.3760/cma.j.issn.2095-2848.2014.01.011.
doi: 10.3760/cma.j.issn.2095-2848.2014.01.011 |
| 35. |
Mi HZ, Wang Q, Tian R, et al. The clinical availability of hydrochloric acid higenamine as a stress medicine in radionuclide myocardial perfusion imaging to diagnose coronary artery disease. J Cardiovascular Pulmonary Dis 2015; 34(6): 486-8. Chinese. doi: 10.3969/j.issn.1007-5062.2015.06.014.
doi: 10.3969/j.issn.1007-5062.2015.06.014 |
| 36. |
Sun Y, Hou P. Hydrochloric acid higenamine load 99Tcm-MIBI myocardial perfusion imaging in the diagnosis of coronary artery disease. China Health Standard Management 2015; 34(6): 486-8. Chinese. doi: 10.3969/j.issn1674-9316.201502.057.Chinese.
doi: 10.3969/j.issn1674-9316.201502.057.Chinese |
| 37. |
Bai H, Fang LG, Xu RY, et al. Efficacy and safety of higenamine hydrochloride stress echocardiography for diagnosis of coronary artery disease. Chin J Ultrasonogr 2018; 27(1): 104-7. Chinese. doi: 10.3760/cma.j.issn.1004-4477.2018.01.003.
doi: 10.3760/cma.j.issn.1004-4477.2018.01.003 |
| 38. |
JV Monmeneu Menadas, García Gonzalez MP, MP Lopez-Lereu, et al. Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry. Int J Cardiovasc Imaging 2022; 38(1): 195-209. doi: 10.1007/s10554-021-02363-4.
doi: 10.1007/s10554-021-02363-4 |
| 39. |
Rai M, Ahlberg AW, Marwell J, et al. Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers. J Nucl Cardiol 2017; 24(2): 724-34. doi: 10.1007/s12350-016-0448-9.
doi: 10.1007/s12350-016-0448-9 pmid: 26902485 |
| 40. |
Heringlake M, Alvarez J, Bettex D, et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev Cardiovasc Ther 2021; 19(4): 325-35. doi: 10.1080/14779072.2021.1905520.
doi: 10.1080/14779072.2021.1905520 |
| 41. |
Xing G, Yi C, Dou P, et al. Recent progress in the development of beta2 adrenergic receptor agonists: a patent review (2015-2020). Expert Opin Ther Pat 2021; 31(3): 239-46. doi: 10.1080/13543776.2021.1865312.
doi: 10.1080/13543776.2021.1865312 |
| 42. | Huang YN, Shi JS, Lu WQ, et al. The effect of higenamine on relieving asthma. Yao Xue Tong Bao 1985; 20(8): 462-4. (Chinese) |
| 43. |
Tsukiyama M, Ueki T, Yasuda Y, et al. Beta2-adrenoceptor-mediated tracheal relaxation induced by higenamine from Nandina domestic. Planta Medica 2009; 75(13): 1393-9. doi: 10.1055/s-0029-1185743.
doi: 10.1055/s-0029-1185743 pmid: 19468973 |
| 44. |
Bai G, Yang Y, Shi Q, et al. Identification of higenamine in Radix Aconiti Lateralis Preparata as a beta2-adrenergic receptor agonist1. Acta Pharmacol Sin 2008; 29(10): 1187-94. doi: 10.1111/j.1745-7254.2008.00859.x.
doi: 10.1111/j.1745-7254.2008.00859.x pmid: 18817623 |
| 45. |
Cho SG, Jabin Z, Bom HH. Safer stress tests for myocardial perfusion imaging. J Nucl Cardiol 2019; 26(2): 629-32. doi: 10.1007/s12350-017-1083-9.
doi: 10.1007/s12350-017-1083-9 |
| 46. | Jiang WQ, Tao SQ, Li JM, et al. Clinical study of the effect of higenamine on ejection fraction and bradyrthmia. Chin J Integr Tradi West Med 1981; 1(1): 6-8. Chinese. |
| 47. | Chen FH, Jiang WP, Zeng GY. Clinical electrophysiological studies of higenamine in sick sinus syndrome. Chin J Integr Traditi West Med 1984; 4(1): 30-31. Chinese. |
| 48. | Fang XY, Jiang WP, Chen FH, et al. Preliminary report of the effect of Fu Zi Yi Hao on sinoatrial node and atrioventricular node in aging. J Geriatircs 1982. 11( 1): 39-41. |
| 49. | Guo SK, Chen KJ, Qian ZZ, et al. To observe the clinical efficacy of hignamine combined with Shengmai in the treatment of bradyarrhythmia. Beijing Medcine 1981; 3(2): 46-7. Chinese. |
| 50. | Wang BK, Chen LY, Shang M, et al. Effects of dl-demethylcoclaurine on electrophysiological properties of porcine myocardial cells. Zhongguo Yao Li Xue Bao 1982; 3(2): 112-7. Chinese. |
| 51. | Gao TL, Zhuang H. The Effect of Fuzi I Hao On the Bradyarrhythmia in the mice. J Tradit Chin Med 1980; 10(2): 71. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
|
